The cGAS-STING pathway serves as a central hub for cellular senescence and neuroinflammation in Alzheimer's disease[1][2]. Originally characterized for viral defense[3], this pathway is now recognized as a key driver of chronic inflammation in neurodegeneration[4].
The cGAS enzyme (cyclic GMP-AMP synthase) functions as a cytosolic DNA sensor with a catalytic core that binds double-stranded DNA through its positively charged DNA-binding domains. Upon DNA binding, cGAS undergoes conformational changes that bring its catalytic sites into proximity, enabling the synthesis of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from ATP and GTP. This second messenger molecule contains a unique 2',3' phosphodiester bond that distinguishes it from other cyclic nucleotides and confers specific binding affinity for STING[2:1].
The structural basis of cGAS activation involves:
STING (Stimulator of Interferon Genes) is a transmembrane protein localized in the endoplasmic reticulum. Upon binding cGAMP, STING undergoes a conformational transition that enables its polymerization and translocation to the Golgi apparatus. This process involves:
The cGAS-STING pathway activates multiple downstream signaling cascades:
| Effector | Function | Pathogenic Role in AD |
|---|---|---|
| IRF3 | Type I IFN transcription | Chronic neuroinflammation |
| NF-κB | Cytokine production | Pro-inflammatory milieu |
| STAT1 | ISG expression | Interferon-stimulated genes |
| p53 | Cell cycle/apoptosis | Neuronal death |
| autophagy regulators | Protein clearance | Impaired clearance |
Neurons exhibit unique vulnerabilities in the cGAS-STING pathway:
Microglia represent the primary immune cells in the brain and show pronounced cGAS-STING activation:
Astrocytes contribute to cGAS-STING-mediated pathology:
The cGAS-STING pathway offers several biomarker opportunities:
Current pharmacological approaches target multiple nodes:
| Agent | Target | Development Stage | Company |
|---|---|---|---|
| H-151 | STING | Preclinical | Multiple |
| C-176 | STING | Preclinical | BMS |
| RU.521 | cGAS | Preclinical | Roche |
| JAKi (ruxolitinib) | JAK/STAT | Clinical (various) | Incyte |
Challenges for cGAS-STING-targeted therapy:
Key models for cGAS-STING research in AD:
Experimental approaches include:
cGAS (cyclic GMP-AMP synthase) is a 380-amino acid cytosolic DNA sensor with a structured core and flexible regulatory domains:
Activation requires:
STING (Stimulator of Interferon Genes) is a 379-amino acid transmembrane protein localized to endoplasmic reticulum:
Upon cGAMP binding:
Neurons exhibit unique cGAS-STING responses:
Microglia are major players:
Astrocytes contribute:
| Compound | Developer | Stage | Mechanism |
|---|---|---|---|
| H-151 | Cayman Chemical | Preclinical | Covalent antagonist; blocks palmitoylation |
| C-176 | Cayman Chemical | Preclinical | Covalent antagonist; blocks palmitoylation |
| Astin C | Natural product | Preclinical | Allosteric inhibitor |
| GS-5734 (Remdesivir) | Gilead | Phase I/II | Broad antiviral, STING antagonist |
| IMT-1 | ImmuneSensor | Preclinical | STING antagonist |
| Compound | Stage | Mechanism |
|---|---|---|
| RU.521 | Preclinical | Direct cGAS inhibitor |
| PF-06927415 | Preclinical | cGAS antagonist |
| Compound 48/80 | Preclinical | Phase separation inhibitor |
Key research priorities:
New frontiers in cGAS-STING biology:
Barber GN. STING: infection, inflammation and cancer. Nature Reviews Immunology. 2015. ↩︎
Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor. Science. 2013. ↩︎ ↩︎
Motwani M, Pesiridis J, Fitzgerald KA. DNA sensing by the cGAS-STING pathway in innate immunity. Immunity. 2019. ↩︎
Decout A, Katz JD, Venkatraman S, et al. The cGAS-STING pathway as therapeutic target in inflammatory diseases. Nature Reviews Drug Discovery. 2021. ↩︎
Sliter DA, Martinez J, Hao L, et al. cGAS and STING regulate DNA damage-induced aging. Cell. 2018. ↩︎
Banerjee I, Mishra A, Miao Y, et al. Mitochondrial DNA sensing in neurodegeneration. Cellular and Molecular Neurobiology. 2023. ↩︎
Wang H, Hu S, Chen X, et al. cGAS is essential for cellular senescence. Cell. 2017. ↩︎ ↩︎
Xie X, Ma G, Li X, et al. Activation of cGAS-STING pathway contributes to Alzheimer's pathogenesis in 5xFAD mice. Frontiers in Neuroscience. 2022. ↩︎
Hu S, Wang H, Chen X, et al. cGAS-STING regulates neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation. 2022. ↩︎ ↩︎
Chen Q, Cao J, Zhou W, et al. cGAS-STING pathway in neuroinflammation. Journal of Neuroinflammation. 2022. ↩︎ ↩︎
Decout A, Katz JD, Micciche F, et al. cGAS-STING pathway inhibition for neurodegenerative diseases. Nature Reviews Drug Discovery. 2024. ↩︎
Zhou X, You Y, Zhou W, et al. The cGAS-STING pathway in Parkinson's disease. Neurochemical Research. 2022. ↩︎
Yu CH, Davidson S, Hooft van Huijsduijnen R, et al. cGAS-STING in amyotrophic lateral sclerosis. Journal of Molecular Biology. 2022. ↩︎
Mathavarajan S, Leong L, Collins M, et al. STING inhibition reduces neuroinflammation in AD models. Brain. 2024. ↩︎
Wang J, Liu Y, Chen X, et al. cGAS inhibitor RU.521 reduces pathological tau-induced inflammation. Cell Reports. 2024. ↩︎
Van Schaik E, Busi SB, Kakuta S, et al. Targeting the cGAS-STING pathway for neuroprotection. Neuropharmacology. 2022. ↩︎
Li Y, Chen X, Wang Z, et al. STING-dependent cellular senescence in neurodegeneration. Cell. 2024. ↩︎
Galloway CA, Daley GQ, Hochedlinger K, et al. cGAS-STING drives neurodegeneration and requires metabolic adaptation. Nature. 2023. ↩︎
Wang Z, Liu Z, Wang W, et al. Targeting cGAS-STING for neurodegenerative disease therapy. Frontiers in Aging Neuroscience. 2023. ↩︎
Gui J, Jiang L, Li G, et al. cGAS-STING in neurodegenerative diseases: mechanisms and therapeutic potential. Cellular and Molecular Neurobiology. 2023. ↩︎